Skip to main content

Table 1 Results for H3255 cells under gefitinib treatment

From: Standardized high-throughput evaluation of cell-based compound screens

Compound

IC50

c low

c up

v

17AAG

0.0275

0.0237

0.0321

0.0901

0.0304

Gefitinib

0.0059

0.005

0.007

0.0858

0.0242

Purvalanol

5.689

3.850

8.406

0.1437

0.1618

Rapamycin

5.957

0.0267

1328

0.0815

2.183

SU11274

NA

NA

NA

0.2413

NA

UO126

8.414

7.218

9.808

0.1727

0.0518

VX680

2.692

0.9192

7.881

0.1226

0.7816

  1. Results of the dose-response experiment for the EGFR-mutant H3255 NSCLC cell line treated with small molecule compounds 17AAG, purvalanol, SU11274, gefitinib, rapamycin, VX680 and U0126. The lowest IC50 value (first column) reveals strong activity of gefitinib, whereas the NA values indicate that the sample is resistant to SU11274 treatment and no IC50 value was calculated. The columns clow and cup show the 95% confidence interval for the IC50 values. The maximum of the standard deviations of the measurements is given in the column , whereas in the last column, v denotes the coefficient of variation of the IC50 values.